Protein expression profile of celiac disease patient with aberrant T cell by two-dimensional difference gel electrophoresis

Annals of the New York Academy of Sciences

Volumn 1109, Issue , 2007, Pages 429-440

  De Re, Valli ^a   Simula, Maria Paola ^a   Caggiari, Laura ^a   Ortz, Nicoletta ^b   Spina, Michele ^a   Da Ponte, Alessandro ^a   De Appolonia, Leandro ^a   Dolcetti, Riccardo ^a   Canzonieri, Vincenzo ^a   Cannizzaro, Renato ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^b General Hospital   (Italy)

Author keywords

2D DIGE; Celiac disease; Enteropathy associated T cell lymphoma; T cell receptor

Indexed keywords

ALEMTUZUMAB; APOLIPOPROTEIN C3; CD52 ANTIGEN; FERRITIN; IMMUNOGLOBULIN M; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE ANTIBODY; T LYMPHOCYTE RECEPTOR; T LYMPHOCYTE RECEPTOR BETA CHAIN; GLYCOPROTEIN; LYMPHOCYTE ANTIGEN RECEPTOR; LYSOPHOSPHOLIPASE;

ADULT; AMINO ACID SEQUENCE; B LYMPHOCYTE; CELIAC DISEASE; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE ASSOCIATION; EOSINOPHIL; FEMALE; HUMAN; IMMUNE RESPONSE; MALE; PROTEIN EXPRESSION; T CELL LYMPHOMA; T LYMPHOCYTE; TWO DIMENSIONAL GEL ELECTROPHORESIS; AGED; ARTICLE; CLASSIFICATION; GENETICS; IMMUNOLOGY; METABOLISM; METHODOLOGY; MIDDLE AGED; PATHOLOGY; PROTEOMICS;

ADULT; AGED; APOLIPOPROTEIN C-III; B-LYMPHOCYTES; CELIAC DISEASE; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; FEMALE; GLYCOPROTEINS; HUMANS; IMMUNOGLOBULIN M; LYSOPHOSPHOLIPASE; MALE; MIDDLE AGED; PROTEOMICS; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; T-LYMPHOCYTES;

EID: 34848862206     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1398.049     Document Type: Conference Paper

References (53)

1. TRIER, J.S. 1991. Celiac sprue. N. Engl. J. Med. 325: 1709-1719.
2. CATASSI, C. et al. 1996. The coeliac iceberg in Italy. A multicentre antigliadin antibodies screening for coeliac disease in school-age subjects. Acta Paediatr. Suppl. 412: 29-35.
3. NOT, T. et al. 1998. Celiac disease risk in the USA: high prevalence of antiendomysium antibodies in healthy blood donors. Scand. J. Gastroenterol. 33: 494-498.
4. HANKEY, G.L. & G.K. HOLMES. 1994. Coeliac disease in the elderly. Gut 35: 65-67.
5. CELLIER, C. et al. 2000. Refractory sprue, coeliac disease, and enteropathy-associated T-cell lymphoma. French Coeliac Disease Study Group. Lancet 356: 203-208.
6. DIETERICH, W. et al. 1997. Identification of tissue transglutaminase as the autoantigen of celiac disease. Nat. Med. 3: 797-801.
7. VADER, W. et al. 2003. The HLA-DQ2 gene dose effect in celiac disease is directly related to the magnitude and breadth of gluten-specific T cell responses. Proc. Natl. Acad. Sci. USA 100: 12390-12395.
8. AL TOMA, A. et al. 2006. Human leukocyte antigen-DQ2 homozygosity and the development of refractory celiac disease and enteropathy-associated T-cell lymphoma. Clin. Gastroenterol. Hepatol. 4: 315-319.
9. LUNDIN, J. et al. 2006. Alemtuzumab treatment of refractory celiac disease type II [abstract]. Gastroenterology 130(Suppl 2): A-666.
10. VERBEEK, W.H., C.J. MULDER & S. ZWEEGMAN. 2006. Alemtuzumab for refractory celiac disease. N. Engl. J. Med. 355: 1396-1397.
11. VIVAS, S. et al. 2006. Alemtuzumab for refractory celiac disease in a patient at risk for enteropathy-associated T-cell lymphoma. N. Engl. J. Med. 354: 2514-2515.
12. KEATING, M.J. et al. 2002. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 99: 3554-3561.
13. LUNDIN, J. et al. 1998. CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma. J. Clin. Oncol. 16: 3257-3263.
14. AL TOMA, A. et al. 2007. Autologous hematopoietic stem cell transplantation in refractory celiac disease with aberrant T-cells. Blood. 109: 2243-2249.
15. DE RE, V. et al. 2006. Type II mixed cryoglobulinaemia as an oligo rather than a mono B-cell disorder: evidence from GeneScan and MALDI-TOF analyses. Rheumatology 45: 685-693.
16. OBERHUBER, G., G. GRANDITSCH & H. VOGELSANG. 1999. The histopathology of coeliac disease: time for a standardized report scheme for pathologists. Eur. J. Gastroenterol. Hepatol. 11: 1185-1194.
17. DE RE V. et al. 2007. Proteins specifically hyperexpressed in a coeliac patient with aberrant T cells. Clin. Exp. Immunol. 148: 402-409.
18. DE RE, V. et al. 2006. HCV-NS3 and IgG-Fc crossreactive IgM in patients with type II mixed cryoglobulinemia and B-cell clonal proliferations. Leukemia 20: 1145-1154.
19. KHOVIDHUNKIT, W. et al. 2004. Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J. Lipid. Res. 45: 1169-1196.
20. MILLER, Y.I. et al. 2003. Oxidized low density lipoprotein and innate immune receptors. Curr. Opin. Lipidol. 14(5): 437-445.
21. KARLSSON, H., P. et al. 2005. Mapping of proteins in low-density lipoprotein using two-dimensional gel electrophoresis and mass spectrometry. Proteomics 5: 551-565.
22. BIRON, C.A. et al. 1999. Function and regulation by innate cytokines. Annu. Rev. Immunol. 17: 189-220.
23. YASUMASU, T. et al. 2006. Effect of plasma lipoproteins on natural killer cell activity in the elderly population. J. Gerontol. A Biol. Sci. Med. Sci. 58: 561-565.
24. ZHOU, X. et al. 1998. Hypercholesterolemia is associated with a T helper (Th) 1/Th2 switch of the autoimmune response in atherosclerotic apo E-knockout mice. J. Clin. Invest. 101: 1717-1725.
25. CABANA, V.G., J.N. SIEGEL & S.M. SABESIN. 1989. Effects of the acute phase response on the concentration and density distribution of plasma lipids and apolipoproteins. J. Lipid. Res. 30: 39-49.
26. FEINGOLD, K. et al. 2006. Effect of endotoxin on cholesterol biosynthesis and distribution in serum lipoproteins in Syrian hamsters. J. Lipid. Res. 34: 2147-2158.
27. SAMMALKORPI, K. et al. 2006. Changes in serum lipoprotein pattern induced by acute infections. Metabolism 37: 859-865.
28. METZGER, S. et al. 1996. Co-regulation of apo A-I, apo C-III and apo A-IV gene expression in human intestinal biopsies. Eur. J. Clin. Invest. 26: 71-75.
29. HUE, S. et al. 2004. A direct role for NKG2D/MICA interaction in villous atrophy during celiac disease. Immunity 21: 367-377.
30. MERESSE, B. et al. 2006. Reprogramming of CTLs into natural killer-like cells in celiac disease. J. Exp. Med. 203: 1343-1355.
31. EXLEY, M. et al. 1997. Requirements for CD1d recognition by human invariant Valpha24+ CD4-CD8- T cells. J. Exp. Med. 186: 109-120.
32. CHAMPAGNE, E. et al. 2005. Role of apolipoproteins in gammadelta and NKT cell-mediated innate immunity. Immunol. Res. 33: 241-255.
33. SCOTET, E. et al. 2005. Tumor recognition following Vgamma9Vdelta2 T cell receptor interactions with a surface F1-ATPase-related structure and apolipoprotein A-I. Immunity 22: 71-80.
34. WOOD, G.M. et al. 1986. Immunoglobulin production by coeliac biopsies in organ culture. Gut 27: 1151-1160.
35. O'MAHONY, S. et al. 1991. Dissociation between systemic and mucosal humoral immune responses in coeliac disease. Gut 32: 29-35.
36. WOOD, G.M. et al. 1987. Jejunal plasma cells and in vitro immunoglobulin production in adult coeliac disease. Clin. Exp. Immunol. 69: 123-132.
37. LANCASTER-SMITH, M., S. JOYCE & P. KUMAR. 1977. Immunoglobulins in the jejunal mucosa in adult coeliac disease and dermatitis herpetiformis after the reintroduction of dietary gluten. Gut 18: 887-891.
38. LANCASTER-SMITH, M. et al. 1976. Cellular infiltrate of the jejunum after reintroduction of dietary gluten in children with treated coeliac disease. J. Clin. Pathol. 29: 587-591.
39. KETT, K. et al. 1990. Secretory immunity in celiac disease: cellular expression of immunoglobulin A subclass and joining chain. Gastroenterology 99: 386-392.
40. BRANDTZAEG, P. et al. 1989. Immunobiology and immunopathology of human gut mucosa: humoral immunity and intraepithelial lymphocytes. Gastroenterology 97: 1562-1584.
41. CRABTREE, J.E., R.V. HEATLEY & M.L. LOSOWSKY. 1989. Immunoglobulin secretion by isolated intestinal lymphocytes: spontaneous production and T-cell regulation in normal small intestine and in patients with coeliac disease. Gut 30: 347-354.
42. SCOTT, B.B., D.G. SCOTT & M.S. LOSOWSKY. 1977. Jejunal mucosal immunoglobulins and complement in untreated coeliac disease. J. Pathol. 121: 219-223.
43. HALSTENSEN, T.S. et al. 1992. Association of subepithelial deposition of activated complement and immunoglobulin G and M response to gluten in celiac disease. Gastroenterology 102: 751-759.
44. MOORTHY, A.V., S.W. ZIMMERMAN & P.E. MAXIM. 1978. Dermatitis herpetiformis and celiac disease: association with glomerulonephritis, hypocomplementia, and circulating immune complexes. JAMA 239: 2019-2020.
45. LAVO, B. et al. 2006. Gliadin challenge-induced jejunal prostaglandin E2 secretion in celiac disease. Gastroenterology 99: 703-707.
46. HALLGREN, R. et al. 1989. Studies on the secretion rate and immunohistochemical localization of granulocyte granule constituents. Am. J. Med. 86: 56-64.
47. KRISTJANSSON, G. et al. 2005. Gut mucosal granulocyte activation precedes nitric oxide production: studies in coeliac patients challenged with gluten and corn. Gut 54: 769-774.
48. COLOMBEL, J.F. et al. 1992. Evidence for a local release of major basic protein. Gut 33: 1190-1194.
49. ACKERMAN, S.J. et al. 2002. Charcot-Leyden crystal protein (galectin-10) is not a dual function galectin with lysophospholipase activity but binds a lysophospholipase inhibitor in a novel structural fashion. J. Biol. Chem. 277: 14589-14568.
50. FURUTA, G.T. et al. 2005. Role for major basic protein. Am. J. Physiol. Gastrointest. Liver Physiol. 7. 89: G890-G897.
51. LOMBARDI, C. & G. PASSALACQUA. 2003. Clinical revision of 1862 cases. Arch. Intern. Med. 163: 1371-1373.
52. DESREUMAUX, P. et al. 1992. Interleukin 5 messenger RNA expression by eosinophils in the intestinal mucosa of patients with coeliac disease. J. Exp. Med. 175: 293-296.
53. LAMKHIOUED, B. et al. 1996. Synthesis of type 1 (IFN gamma) and type 2 (IL-4, IL-5, and IL-10) cytokines by human eosinophils. Ann. N. Y. Acad. Sci. 796: 203-208.